肿瘤治疗始终面临着诸多挑战，提高治疗的特异性、疗效并降低副作用是关键目标。免疫疗法作为一种新兴的治疗手段，在过去几十年中得到了广泛研究。嵌合抗原受体 T（CAR-T）细胞疗法在血液系统恶性肿瘤治疗中取得了显著成效，但存在生产成本高昂、制备过程复杂以及潜在慢性毒副作用等问题。

中国国家药监局药品审评中心 (CDE)官网最新公示，诺华 (NVS.US)申报的1类新药PIT565获得一项新的临床试验默示许可，拟开发治疗系统性红斑狼疮 (SLE)。公开资料显示，这是诺华在研的一款抗CD3/CD19/CD2的三特异性抗体，此前已经在中国获批针对B细胞恶性肿瘤的IND。

首个专门针对清除潜伏HIV-1细胞的T细胞受体（TCR）疗法已经通过了初步临床试验。这种双特异性免疫疗法可以靶向并清除那些长期携带HIV的CD4+细胞，也就是所谓的“病毒储存库”。

Founded in 1999, TCR is today a major business-to-business service provider in the GSE sector. TCR implements the rental, repair and maintenance of Ground Support Equipment (GSE) and owns over 50,000 ...

The Belo Horizonte street race will join the 2025 TCR South America calendar on August 16-17 in Brazil. “Our presence at the BH Stock Festival is another step towards the growth and consolidation of ...

"Obesity is gradually eroding human health," and the global prevalence of obesity (BMI > 30) is predicted to reach 25 % by 2035, affecting nearly 1.9 billion people. The demand for medications to ...

1 Immunology Graduate Program, Baylor College of Medicine, Houston, TX, United States 2 Department of Pathology, University of Utah, Salt Lake City, UT, United States Introduction: Chimeric antigen ...